# Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

> **NCT03216070** · PHASE4 · UNKNOWN · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 12 (estimated)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Dasatinib 50 MG

## Key facts

- **NCT ID:** NCT03216070
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04-01
- **Primary completion:** 2018-10-01
- **Final completion:** 2018-10-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216070, "Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03216070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*